NR1H4 and metabolic dysfunction-associated steatohepatitis: One such trial is the phase 2 NCT02781584, in which safety and efficacy of fenofibrate and icosapent ethyl (Vascepa) to mitigate elevated levels of triglyceride (≥150 and <500 mg/dL) in NASH/NAFLD patients previously treated with CILO (FXR agonist) and FIR (aceyl-CoA carboxylase inhibitor) was assessed.